Hybio Pharmaceutical Co., Ltd. announced a private placement not exceed 50,000,000 A shares for gross proceeds of not exceed CNY 254,120,000 on August 11, 2023. The transaction will include participation from not more than 35. The type of stock issued this time is domestically listed CNY ordinary A shares.

The pricing base date of this issuance is the first day of the issuance period of the company?s stock issuance, and the issue price shall not be lower than 80% of the company?s average stock trading price in the 20 trading days prior to the pricing base date. The stocks issued to specific objects through simplified procedures this time cannot be transferred within 6 months from the date of completion of this issuance. This has been approved in the eighteenth meeting of the fifth board of directors and and the 13th session of the company?s 5th supervisory board approved the 2023 issuance of shares to specific investors and is subject to the approvals of the the Shenzhen Stock Exchange needs to review and make review opinions on whether the listed company meets the issuance conditions and information disclosure requirements and The China Securities Regulatory Commission must make a decision on the approval or disapproval of the registration application of the listed company.